# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001140361-23-019398
Filing Date
2023-04-20
Accepted
2023-04-20 16:30:41
Documents
6
Period of Report
2023-06-16

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | ny20008400x1_pre14a.htm | PRE 14A | 943056
2 |  | ny20008400x1_pc01.jpg | GRAPHIC | 584563
3 |  | ny20008400x1_pc02.jpg | GRAPHIC | 324182
4 |  | ny20008400x1_pvp01x1.jpg | GRAPHIC | 128030
5 |  | ny20008400x1_pvp02.jpg | GRAPHIC | 129394
6 |  | ny20008400x1_pvp03x1.jpg | GRAPHIC | 114274
| Complete submission text file | 0001140361-23-019398.txt |  | 2706592

Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-11460 | Film No.: 23833519
SIC: 2834 Pharmaceutical Preparations